Form 4: Ultragenyx Executive Sells Shares

EVP and Chief Legal Officer Karah Parschauer sold 1,899 shares of Ultragenyx Pharmaceutical Inc. common stock.

Summary

• Karah Parschauer, EVP and Chief Legal Officer of Ultragenyx Pharmaceutical Inc., sold 1,899 shares of common stock.
• The transaction occurred on June 15, 2026, at a price of $24.62 per share.
• The sale was executed pursuant to a Rule 10b5-1 trading plan.
• Following the transaction, the reporting person retains beneficial ownership of 94,462 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed via a pre-planned 10b5-1 arrangement, which is standard practice for corporate executives.

Positives

• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, which is a standard mechanism for executives to sell shares without concerns regarding insider trading.

Negatives

• The sale represents a reduction in the executive's direct equity stake in the company.

Risks

• Insider selling can sometimes be perceived negatively by the market, potentially signaling that management believes the stock price is fully valued.

Future Outlook

No specific forward-looking guidance regarding company performance was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling under 10b5-1 plans is common in the biotechnology sector and typically reflects personal financial planning rather than a change in outlook on company fundamentals.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate officers to manage equity holdings while maintaining regulatory compliance.

Stakeholder Impact

• Minimal impact expected as the transaction was pre-planned and represents a small portion of the executive's total holdings.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Ultragenyx, RARE, Insider Trading, Form 4, Biotech, Executive Compensation